,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'breast', 'destiny-breast04', 'astrazeneca']
much-anticipated news from presented by dr. shanu modi: results of destiny-breast04, a randomized, phase 3 study: trastuzumab deruxtecan versus treatment of physician s choice in patients with her2-low unresectable and/or metastatic breast cancer #asco22 b1 2:17pm
Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements